Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
d3590771-806b-4754-a455-38113bfedfca | For metastatic patients whose disease is ER+ and/or PR+ the following criteria should be met: Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Rapidly progressing or life threatening disease, as determined by the investigator. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Patients who received hormonal therapy and are no longer benefiting from this therapy. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | A tumor lesion from the patient biopsied before or during screening shows either: Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Overexpression of the HER2 protein, as determined by immunohistochemistry (IHC, with result IHC 3+) or Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Amplification of the HER2 gene as determined by FISH (at least 4 fold i.e. at least 8 copies). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Note: Overexpression/amplification measurements must be performed on a metastatic lesion in all cases where such a lesion is sufficiently easily accessible. If however such a biopsy is not possible, then these measurements can be performed on the primary tumor. Use of the primary tumor is to be documented and justified. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Ten FFPE tissue sections of the tumor on which the HER2 overexpression/amplification has been done -if available-may be requested. These may be used to retrospectively carry out part of the translational research (i.e. analysis of EGF receptor activity and of the presence of immune effector cells, refer to Section 7). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has at least one measurable lesion according to RECIST criteria. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has ECOG status of 0 or 1. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has adequate bone marrow reserve as indicated by: Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | White blood cell count >/= 3,000/mm3. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Neutrophil count >/= 1,500/mm3. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Platelet count >/= 100,000/mm3. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Hemoglobin levels >/= 10.0 g/dl. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has adequate renal function as shown by the creatinine levels (i.e. within the normal range). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has adequate hepatic function as shown by serum bilirubin levels i.e: Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Serum bilirubin levels within the normal limits. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Both AST and ALT levels <1.5 times the ULN. Note: However, for patients with liver metastasis, a serum bilirubin level <1.5 times the ULN and both AST and ALT levels <3 times the ULN will be accepted. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to treatment, have a negative pregnancy test and continue such precautions for two months after completion of the study treatment. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable, as mentioned in the product label) for example abstinence, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS), vasectomy with documented azoospermia of the sole male partner or double barrier method (condom or occlusive cap plus spermicidal agent). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | For azoospermia, "documented" refers to the outcome of the investigator's/ designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Post-menopause: Menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential by ovarian failure. A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile at the appropriate age e.g. > 45 years. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Able to swallow and retain oral medication. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | In the view of the investigator, the patient can and will comply with the requirements of the protocol. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The following criteria should be checked at the time of study entry. If any apply, the patient must not be included in the study: Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has received > 300 mg/m2 doxorubicin (cumulative dose) or > 600 mg/m2 epirubicin (cumulative dose). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration. (See also section 5.3.2.). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has received any investigational or non-registered product (drug or vaccine) other than the study treatment(s) within 30 days preceding the first dose of study treatment, or planned use during the study period. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient requires concomitant treatment with systemic corticosteroids or any immunosuppressive agents. The use of prednisone, or equivalent, <0.5 mg/kg/day (absolute maximum 40 mg/day), or inhaled corticosteroids or topical steroids is permitted. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has a malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Patients with ulcerative colitis. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy (found by ECG) or previous myocardial infarction. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has any acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has current active hepatic or biliary's disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient presents with autoimmune disease (vitiligo and autoimmune thyroid disease is not an exclusion criterion). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has a known family history of congenital or hereditary immunodeficiency. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has a history of anaphylaxis or severe allergic reaction to vaccines or unknown allergens. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib. These include other anilinoquinazolines, such as gefitinib (Iressa), erlotinib (Tarceva), or other chemically related compounds or excipients. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient is known to be positive for the Human Immunodeficiency Virus (HIV). Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has (or has had) previous or concomitant malignancies at other sites except effectively treated: Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Non-melanoma skin cancers or carcinoma in situ of the cervix Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | Malignancy that has been in remission for > 2 years and is considered highly likely to have been cured. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has any psychiatric or addictive disorder that may compromise her ability to give informed consent, or to comply with the trial procedures. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient has any other condition that in the opinion of the investigator might jeopardize the patient's safety or ability to comply with the requirements of the study. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
d3590771-806b-4754-a455-38113bfedfca | The patient is pregnant or lactating. Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Arm A: Endocrine Therapy (ET) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Arm B: ET With Bevacizumab (ET-B) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Bevacizumab both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 1: Yoga Intervention secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Arm A: Endocrine Therapy (ET) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Arm B: ET With Bevacizumab (ET-B) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Bevacizumab both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga Intervention secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Arm A: Endocrine Therapy (ET) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Arm B: ET With Bevacizumab (ET-B) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Bevacizumab both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Yoga: Yoga sessions secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Arm A: Endocrine Therapy (ET) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Arm B: ET With Bevacizumab (ET-B) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Bevacizumab both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Arm 2: Educational Wellness Group secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Arm A: Endocrine Therapy (ET) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Arm B: ET With Bevacizumab (ET-B) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Bevacizumab both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Educational Wellness Group secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Arm A: Endocrine Therapy (ET) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Letrozole both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Fulvestrant both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |
941b960f-8d57-4830-9d4c-8e96765ba76c | primary trial: Education: Educational Wellness Group secondary trial: Arm B: ET With Bevacizumab (ET-B) both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. | 0 |